Acadian Asset Management
GLUE icon

Acadian Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Acadian Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,513
Closed -$1.29M – 2080
2026
Q1 		$1.29M Sell
78,513
-169,342
-68% -$3.24M ﹤0.01% 1083
2025
Q4 		$3.88M Buy
247,855
+44,305
+22% +$597K 0.01% 721
2025
Q3 		$1.51M Buy
203,550
+157,408
+341% +$834K ﹤0.01% 958
2025
Q2 		$207K Buy
46,142
+29,757
+182% +$133K ﹤0.01% 1300
2025
Q1 		$76K Buy
+16,385
New +$100K ﹤0.01% 1387
2024
Q4 		– Sell
-110,835
Closed -$586K – 1832
2024
Q3 		$586K Buy
110,835
+12,278
+12% +$62K ﹤0.01% 1046
2024
Q2 		$366K Buy
98,557
+43,009
+77% +$219K ﹤0.01% 1299
2024
Q1 		$390K Buy
55,548
+26,687
+92% +$158K ﹤0.01% 1064
2023
Q4 		$161K Buy
+28,861
New +$113K ﹤0.01% 1276

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Acadian Asset Management's GLUE Position: Q2 2026 in Review

Acadian Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 78,513 shares — an estimated $1.29M sold.

Acadian Asset Management first reported a position in GLUE in Q4 2023 and held it in 9 quarters. The position peaked at $3.88M in Q4 2025. 146 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Acadian Asset Management reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 78,513 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Acadian Asset Management first reported a position in Monte Rosa Therapeutics in Q4 2023 and held it in 9 quarters.
  • Acadian Asset Management's Monte Rosa Therapeutics position peaked at $3.88M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.